RayzeBio, Inc. Common Stock
RYZB
Updated: 23/09/2026, 15:27:34
No historical data available
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
No summaries found.
- Share price
- $62.49
- Market cap
- $3.75B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Kenneth Song
- Employees
- 88
- IPO date
- 15/09/2023
- Beta
- 3.79
- Last dividend
- $0.00
- Day range
- $62.48 – $62.50
- 52-week range
- $17.95 – $62.51
- 1-day performance
- 0.02%
- 1-year performance
- 248.13%
- Current drawdown (1Y)
- -0.03%
- CIK
- 0001825367
- CUSIP
- 75525N107
- ISIN
- US75525N1072
- Created
- 07/12/2025, 14:05:50
- Last update
- 23/09/2026, 15:27:34
Track RayzeBio, Inc. Common Stock with an AI analyst
See which prediction-market events move RYZB, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.